Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tenax Therapeutics ( (TENX) ) has issued an update.
On January 6, 2026, Tenax Therapeutics disclosed that its Chief Medical Officer, Dr. Stuart Rich, entered into a second amendment to his executive employment agreement originally dated January 15, 2021 and previously amended on June 12, 2024. Effective January 1, 2026, Dr. Rich will shift to an average four-day workweek in his role as CMO, with his annual base salary prorated to reflect the reduced schedule, a change approved by the board on December 22, 2025 that adjusts executive compensation and time commitment without indicating broader operational changes.
The most recent analyst rating on (TENX) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Tenax Therapeutics stock, see the TENX Stock Forecast page.
Spark’s Take on TENX Stock
According to Spark, TipRanks’ AI Analyst, TENX is a Neutral.
TENX scores in the mid-range primarily due to very weak financial performance (no revenue, widening losses, and ongoing cash burn) despite a strong, debt-free balance sheet. Technicals are a meaningful positive with a clear uptrend and positive momentum indicators, but valuation remains unattractive due to continued losses and no dividend yield.
To see Spark’s full report on TENX stock, click here.
More about Tenax Therapeutics
Average Trading Volume: 147,582
Technical Sentiment Signal: Sell
Current Market Cap: $80.23M
See more data about TENX stock on TipRanks’ Stock Analysis page.